TORONTO, Ontario, May 13, 2026
Medicenna Therapeutics announced that the first patient has been enrolled and dosed in the NEO-CYT clinical trial, an investigator-initiated Phase 1b study evaluating MDNA11, the company’s long-acting IL-2 Superkine, in combination with immune checkpoint inhibitors for patients with high-risk surgically resectable Stage III melanoma. The study is being conducted in collaboration with Fondazione Melanoma Onlus in Italy and represents an important step forward in Medicenna’s strategy to expand the clinical development of its next-generation cytokine-based immunotherapies. The NEO-CYT study is designed to evaluate whether adding MDNA11 to standard-of-care immunotherapy prior to surgery can improve anti-tumor immune responses and potentially enhance long-term clinical outcomes for melanoma patients. The announcement further strengthens growing industry interest in engineered cytokine therapies capable of overcoming limitations historically associated with conventional interleukin-based cancer treatments.
MDNA11 Combines IL-2 Superkine With Checkpoint Inhibitors
According to Medicenna, the NEO-CYT trial will evaluate MDNA11 in combination with nivolumab, with or without ipilimumab, in patients diagnosed with high-risk cutaneous melanoma prior to surgical tumor removal. MDNA11 is a proprietary long-acting IL-2 Superkine engineered to selectively activate cancer-fighting immune cells such as CD8 T cells and natural killer (NK) cells while minimizing stimulation of regulatory T cells that can suppress anti-tumor immunity. Traditional IL-2 therapies have historically demonstrated significant toxicity and limited therapeutic windows, restricting broader clinical adoption despite their anti-cancer potential. Medicenna’s engineered Superkine platform was specifically developed to improve selectivity, durability, and tolerability compared with earlier cytokine therapies.
The company stated that the neoadjuvant trial design allows researchers to directly analyze tumor tissue and immune-cell activity before and after treatment, providing critical biological insights into how MDNA11 may enhance responses to checkpoint inhibition. Neoadjuvant immunotherapy approaches have become an increasingly important area of oncology research because early immune activation prior to surgery may improve long-term disease control and reduce recurrence risk in aggressive cancers such as melanoma. Investigators participating in the NEO-CYT study will assess multiple endpoints including safety, pathological response rates, immune activation markers, and surgical outcomes. Medicenna believes the trial may help establish proof-of-concept for combining engineered cytokines with checkpoint inhibitors in earlier-stage solid tumors.
The launch of patient dosing follows encouraging data from Medicenna’s ongoing ABILITY-1 Phase 1/2 clinical trial, which is evaluating MDNA11 in advanced solid tumors both as monotherapy and in combination with KEYTRUDA (pembrolizumab). Earlier findings demonstrated evidence of durable immune activation, tumor shrinkage in selected patients, and a manageable safety profile, reinforcing the therapeutic potential of the company’s IL-2 engineering platform. Industry analysts believe selective cytokine therapies may become increasingly important in immuno-oncology as companies seek alternatives capable of improving efficacy while reducing immune-related toxicities associated with traditional cytokine treatments.
Advertisement
Medicenna Expands Position in Immuno-Oncology Market
The NEO-CYT study also highlights Medicenna’s broader strategy to position itself within the rapidly evolving immuno-oncology and cytokine therapeutics market. The company has developed multiple proprietary platforms including Superkine™, BiSKIT™, and T-MASK™, which are designed to create highly selective cytokine-based therapies for cancer, autoimmune diseases, and inflammatory disorders. In addition to MDNA11, Medicenna is advancing MDNA113, a first-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional Superkine currently progressing toward IND-enabling studies. The company recently presented preclinical data demonstrating improved safety and tumor-targeting properties for MDNA113 at the American Association for Cancer Research (AACR) 2026 Annual Meeting.
The global cytokine therapeutics sector has attracted renewed pharmaceutical investment as advances in protein engineering, tumor targeting, and immune-cell selectivity enable development of next-generation immunotherapies with potentially improved tolerability profiles. While early cytokine therapies often faced significant toxicity challenges, biotechnology companies are increasingly using engineered cytokines, masked immune agonists, and bifunctional immune modulators to create more precise anti-cancer immune activation strategies. Melanoma remains one of the leading cancers treated with immunotherapy, making it a strategically important indication for emerging cytokine platforms seeking to demonstrate clinical value in combination with checkpoint inhibitors.
Medicenna executives stated that dosing the first patient in the NEO-CYT trial marks another important milestone in advancing the company’s vision of delivering more selective and potent cytokine-based immunotherapies for patients with difficult-to-treat cancers. As competition intensifies across immuno-oncology and next-generation immune modulation technologies, the company aims to differentiate its platform through engineered selectivity, enhanced tumor targeting, and combination treatment strategies designed to improve clinical outcomes across multiple solid tumor types.
Source: Medicenna press release
